Gliosarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GLS001 MIFTS: 55	Gliosarcoma malady Categories: Rare diseases, Neuronal diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Aliases & Classifications for Gliosarcoma

Sources:
¹¹Disease Ontology, ¹³DISEASES, ³¹ICD10 via Orphanet, ³⁹MeSH, ⁴⁵NCIt, ⁴⁸NIH Rare Diseases, ⁵⁰Novoseek, ⁵⁴Orphanet, ⁶²SNOMED-CT, ⁶⁸UMLS, ⁶⁹UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Gliosarcoma:

Name: Gliosarcoma ¹¹ ⁴⁸ ⁵⁴ ⁵⁰ ³⁹ ¹³ ⁶⁸

Glioblastoma with Sarcomatous Component ¹¹

Sarcomatous Glioblastoma ⁴⁸

Characteristics:

Orphanet epidemiological data:

⁵⁴

gliosarcoma:
Inheritance: Not applicable; Age of onset: Adult

Classifications:

MalaCards categories:
Global: Rare diseases, Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the nervous system

Diseases of myoneural junction and muscle

Primary disorders of muscles

Primary disorder of muscle, unspecified

Orphanet: ⁵⁴

Rare neurological diseases

External Ids:

Disease Ontology¹¹ DOID:3071

MeSH³⁹ D018316

NCIt⁴⁵ C3796

SNOMED-CT⁶² 189909006, 189918008, 35262004

Orphanet⁵⁴ ORPHA251576

ICD10 via Orphanet³¹ G71.9

UMLS via Orphanet⁶⁹ C0206726

UMLS⁶⁸ C0206726

Summaries for Gliosarcoma

Sources:
³⁶MalaCards, ⁷¹Wikipedia
See all MalaCards sources

Wikipedia:⁷¹ Gliosarcoma is a rare type of glioma, a cancer of the brain that comes from glial, or supportive, brain... more...

MalaCards based summary: Gliosarcoma, also known as glioblastoma with sarcomatous component, is related to medulloblastoma and ganglioglioma, and has symptoms including headache and seizures. An important gene associated with Gliosarcoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways are Vemurafenib Pathway, Pharmacodynamics and Alzheimers Disease Pathway. Affiliated tissues include brain, bone and t cells, and related mouse phenotypes are hearing/vestibular/ear and no phenotypic analysis.

Related Diseases for Gliosarcoma

Sources:
²⁰GeneAnalytics, ²¹GeneCards
See all MalaCards sources

Diseases related to Gliosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)

id	Related Disease	Score	Top Affiliating Genes
1	medulloblastoma	30.3	GFAP, MGMT, NES, TP53
2	ganglioglioma	30.2	GFAP, IDH1, TP53
3	giant cell glioblastoma	29.5	EGFR, GFAP, IDH1, MGMT, NES, PTEN
4	adult brainstem gliosarcoma	11.9
5	empty sella syndrome	10.9	GFAP, NES
6	anaplastic oligodendroglioma	10.9	GFAP, NES
7	skin meningioma	10.8	GFAP, TP53
8	central centrifugal cicatricial alopecia	10.8	EGFR, GFAP, MGMT
9	glomeruloid hemangioma	10.8	GFAP, TP53
10	papillary glioneuronal tumor	10.8	GFAP, IDH1
11	infiltrating lipoma	10.7	GFAP, TP53
12	brain glioma	10.7	GFAP, NES, TP53
13	chiari malformation type 4	10.7	FGFR3, GFAP
14	intracystic papillary adenoma	10.7	GFAP, IDH1, NES
15	peptic ulcer disease	10.7	EGFR, TP53
16	mixed epithelial stromal tumour	10.7	GFAP, NES, TP53
17	bilateral retinoblastoma	10.7	CCND3, RB1, TP53
18	foramen magnum meningioma	10.7	GFAP, NES, TP53
19	pharynx cancer	10.7	CCND3, RB1, TP53
20	ascending colon cancer	10.7	CCND3, RB1, TP53
21	renal pelvis inverted papilloma	10.7	GFAP, TP53
22	flnb-related disorders	10.7	FGFR1, FGFR3
23	plasmalogens synthesis deficiency isolated	10.7	FGFR1, FGFR3
24	schwannoma of twelfth cranial nerve	10.7	GFAP, LZTR1, TP53
25	peritoneal benign neoplasm	10.6	GFAP, LZTR1, TP53
26	ovarian small cell carcinoma	10.6	EGFR, SNAI2, TP53
27	oral lichen planus	10.6	EGFR, MGMT, TP53
28	osteopetrosis and infantile neuroaxonal dystrophy	10.6	FGFR1, FGFR3, NES
29	cervical alveolar soft part sarcoma	10.6	GFAP, NES
30	cystinosis, nephropathic	10.6	IDH1, TP53
31	multidrug-resistant tuberculosis	10.6	FGFR3, RB1, TP53
32	maxillary sinus squamous cell carcinoma	10.6	IDH1, TP53
33	spinal cord glioma	10.6	GFAP, IDH1, TP53
34	tamoxifen-related endometrial lesion	10.6	EGFR, TP53
35	pasli disease	10.6	FGFR3, TP53
36	renal tubular acidosis, distal, autosomal recessive	10.6	EGFR, GFAP, PTEN
37	vulvar benign neoplasm	10.6	GFAP, TP53
38	protoplasmic astrocytoma	10.6	GFAP, IDH1, TP53
39	pleomorphic xanthoastrocytoma	10.6	IDH1, TP53
40	glomus tumor	10.6	GFAP, PTEN
41	hypersensitivity reaction type ii disease	10.6	GFAP, TP53
42	stenosis of lacrimal sac	10.5	CCND3, GFAP, NES, RB1, TP53
43	compartment syndrome	10.5	GFAP, PTEN, TP53
44	brainstem intraparenchymal clear cell meningioma	10.5	GFAP, TP53
45	anus disease	10.5	EGFR, MGMT, TP53
46	intrahepatic bile duct cystadenoma	10.5	GFAP, IDH1, MGMT, TP53
47	cervical adenoid cystic carcinoma	10.5	GFAP, IDH1, MGMT, TP53
48	melanotic medulloblastoma	10.5	GFAP, IDH1, PTEN
49	familial renal oncocytoma	10.5	FGFR3, TP53
50	trigonocephaly 1	10.5	FGFR1, FGFR3

Graphical network of the top 20 diseases related to Gliosarcoma:

Symptoms & Phenotypes for Gliosarcoma

Sources:
⁴¹MGI, ⁶⁸UMLS
See all MalaCards sources

UMLS symptoms related to Gliosarcoma:

headache, seizures

MGI Mouse Phenotypes related to Gliosarcoma according to GeneCards Suite gene sharing:

⁴¹ (show all 24)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hearing/vestibular/ear	MP:0005377	10.1	EGFR, FGFR1, FGFR3, FREM2, PPARG, RB1
2	no phenotypic analysis	MP:0003012	9.9	EGFR, FGFR1, FGFR3, MGMT, PPARG, RB1
3	pigmentation	MP:0001186	9.9	EGFR, FREM2, PTEN, RB1, SNAI2, TP53
4	liver/biliary system	MP:0005370	9.9	CCND3, EGFR, PPARG, PTEN, RB1, TACC3
5	muscle	MP:0005369	9.8	EGFR, FGFR1, FREM2, GFAP, PPARG, PTEN
6	limbs/digits/tail	MP:0005371	9.8	EGFR, FGFR1, FGFR3, FREM2, PTEN, RB1
7	respiratory system	MP:0005388	9.8	CCND3, EGFR, FGFR3, FREM2, IDH1, PTEN
8	craniofacial	MP:0005382	9.7	EGFR, FGFR1, FGFR3, FREM2, RB1, SNAI2
9	neoplasm	MP:0002006	9.7	CCND3, EGFR, FGFR3, MGMT, PPARG, PTEN
10	embryo	MP:0005380	9.6	EGFR, FGFR1, FREM2, PPARG, PTEN, RB1
11	reproductive system	MP:0005389	9.6	EGFR, FGFR1, FGFR3, FREM2, PPARG, PTEN
12	renal/urinary system	MP:0005367	9.4	EGFR, FGFR1, FGFR3, FREM2, PPARG, PTEN
13	endocrine/exocrine gland	MP:0005379	9.4	CCND3, EGFR, FGFR1, MGMT, NFKBIA, PPARG
14	integument	MP:0010771	9.4	EGFR, FGFR1, FGFR3, FREM2, NFKBIA, PPARG
15	skeleton	MP:0005390	9.3	EGFR, FGFR1, FGFR3, FREM2, IDH1, PPARG
16	normal	MP:0002873	9.3	CCND3, EGFR, FGFR1, FGFR3, GFAP, NFKBIA
17	vision/eye	MP:0005391	9.2	CCND3, EGFR, FGFR1, FGFR3, FREM2, GFAP
18	digestive/alimentary	MP:0005381	9.1	EGFR, FGFR1, FGFR3, GFAP, PTEN, RB1
19	cardiovascular system	MP:0005385	9.0	CCND3, EGFR, FGFR1, FREM2, GFAP, PPARG
20	immune system	MP:0005387	8.9	CCND3, EGFR, FGFR1, FGFR3, GFAP, IDH1
21	hematopoietic system	MP:0005397	8.9	CCND3, EGFR, FGFR1, FGFR3, IDH1, LZTR1
22	growth/size/body region	MP:0005378	8.6	CCND3, EGFR, FGFR1, FGFR3, FREM2, GFAP
23	homeostasis/metabolism	MP:0005376	8.6	CCND3, EGFR, FGFR1, FGFR3, GFAP, IDH1
24	mortality/aging	MP:0010768	8.5	CCND3, EGFR, FGFR1, FGFR3, FREM2, GFAP

Drugs & Therapeutics for Gliosarcoma

Sources:
¹BitterDB, ⁴ClinicalTrials, ⁷Cochrane Library, ¹⁰DGIdb, ¹⁴DrugBank, ²⁹HMDB, ³³IUPHAR, ⁴⁶NDF-RT, ⁵⁰Novoseek, ⁵⁶PharmGKB, ⁶⁸UMLS
See all MalaCards sources

Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 400)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Procarbazine

approved

Phase 3, Phase 1, Phase 2

671-16-9

4915

Synonyms:

1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine

2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine

366-70-1 (mono-hydrochloride)

4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide

4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide

671-16-9

AC-4547

AC1L1J8E

Ambap671-16-9

BIDD:GT0183

BPBio1_001369

BRN 0958270

BSPBio_001244

Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)

C07402

C12H19N3O

CAS-366-70-1

CB 400-497

CCRIS 2389

CHEMBL1321

CID4915

D08423

DB01168

EINECS 211-582-2

HMS2090J09

HSDB 3250

I01-8931

IBZ

Ibenzmethyzin

Ibenzmethyzine

LS-7671

MBH

MIH

MolPort-005-940-370

N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide

N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide

N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine

N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide

N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide

N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide

N-Isopropyl-α-(2-methylhydrazino)-p-toluamide

N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide

NCGC00016438-01

NCGC00016438-02

NCI60_041703

NCIOpen2_004074

NSC-77213

Natulan

Natulanar

PCX

Prestwick0_001112

Prestwick1_001112

Prestwick2_001112

Prestwick3_001112

Procarbazin

Procarbazin [German]

Procarbazina

Procarbazina [INN-Spanish]

Procarbazine (INN)

Procarbazine Monohydrochloride

Procarbazine [INN:BAN]

Procarbazinum

Procarbazinum [INN-Latin]

Ro 4-6467

Ro 4-6467/1

SPBio_003112

SRI-10847

UNII-35S93Y190K

p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide

p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide

procarbazine

Trioxsalen

approved

Phase 3, Phase 1

3902-71-4

5585

Synonyms:

2',4,8-Trimethylpsoralen

4,5',8-Trimethylpsoralen

4,8,5'-Trimethylpsoralen

6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone

Trimethylpsoralen

Trioxisaleno

Trioxsalen

Trioxysalen

Trioxysalene

Trioxysalenum

Trisoralen

trimethylpsoralen

trioxysalen

trisoralen

Dacarbazine

approved, investigational

Phase 3, Phase 2, Phase 1

674

4342-03-4

5351166

Synonyms:

(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide

(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide

(Dimethyltriazeno)imidazolecarboxamide

37626-23-6

4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide

4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide

4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide

4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide

4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide

4-(Dimethyltriazeno)imidazole-5-c arboxamide

4-(Dimethyltriazeno)imidazole-5-carboxamide

4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide

4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide

4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide

4342-03-4

5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide

5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide

5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide

5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide

5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide

5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide

5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide

5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide

5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide

5-(Dimethyltriazeno)-4-imidazolecarboxamide

5-(Dimethyltriazeno)imidazole-4-carboxamide

5-(Dimethyltriazeno)imidazole-4-carboximide

5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide

5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide

94361-71-4

AC1NQXVV

AC1NS01W

AC1NS4BN

AI3-52825

BPBio1_000428

BRD-K35520305-001-07-8

BSPBio_000388

BSPBio_002091

Biocarbazin

Biocarbazine

Biocarbazine R

C6H10N6O

CAS-891986

CCRIS 190

CHEBI:4305

CHEMBL476

CID5281007

CID5351166

CID5353562

Carboxamide, Dimethyl Imidazole

D00288

D003606

D2390_SIGMA

D3634

DB00851

DIC

DTCI

DTIC

DTIC Dome

DTIC, DTIC-Dome, Dacarbazine

DTIC-Dome

DTICDome

DTIE

Dacarbazin

Dacarbazina

Dacarbazine

Dacarbazine (JAN/USP/INN)

Dacarbazine [USAN:INN:BAN:JAN]

Dacarbazino

Dacarbazino [INN-Spanish]

Dacarbazinum

Dacarbazinum [INN-Latin]

Dacatic

Decarbazine

Deticene

Di-me-triazenoimidazolecarboxamide

Di-methyl-triazenoimidazolecarboxamide

Dimethyl Imidazole Carboxamide

Dimethyl Triazeno Imidazole Carboxamide

Dimethyltriazenoimidazolecarboxamide

DivK1c_000326

Dtic-Dome

Dtic-Dome (TN)

Dtic-dome (tn)

EINECS 224-396-1

HE1150000

HMS1569D10

HMS2090A20

HMS2091I20

HMS501A08

HSDB 3219

I06-2280

I14-1659

ICDMT

ICDT

IDI1_000326

Imidazole Carboxamide

Imidazole Carboxamide, Dimethyl

Imidazole carboxamide

KBio1_000326

KBio2_001364

KBio2_003932

KBio2_006500

KBio3_001311

KBioGR_000896

KBioSS_001364

LS-119

MLS001332543

MLS001332544

MolPort-003-666-153

MolPort-003-846-120

MolPort-006-709-420

NCGC00016986-01

NCGC00091861-01

NCGC00091861-02

NCGC00091861-03

NCGC00091861-04

NCI-C04717

NCI60_004053

NCIMech_000261

NINDS_000326

NIOSH/HE1150000

NPFAPI-05

NSC 45388

NSC-45388

NSC45388

Prestwick0_000574

Prestwick1_000574

Prestwick2_000574

Prestwick3_000574

Prestwick_904

S1221_Selleck

SMP2_000251

SMR000857131

SPBio_001075

SPBio_002607

SPECTRUM1500218

ST51014976

Spectrum2_001148

Spectrum3_000366

Spectrum4_000308

Spectrum5_000823

Spectrum_000884

UNII-7GR28W0FJI

WLN: T5M CNJ DVZ ENUNN1&1

dacarbazine

Bevacizumab

approved, investigational

Phase 3, Phase 2, Phase 1

1968

216974-75-3

Synonyms:

216974-75-3

Avastin

Avastin (TN)

Bevacizumab

Bevacizumab (genetical recombination)

Bevacizumab (genetical recombination) (JAN)

D06409

R-435

anti-VEGF monoclonal antibody

antiVEGF

bevacizumab

Lomustine

approved

Phase 3, Phase 1

13010-47-4

3950

Synonyms:

(Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea

(Cloro-2-etil)-1-cicloesil-3-nitrosourea

(Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]

1-(2-Chloroethyl)-3-cyclohexylnitrosourea

13010-47-4

AC-10564

AC1L1H2T

AI3-52779

BRN 2125058

Belustine

Bristol Myers Squibb Brand of Lomustine

Bristol-Myers Squibb Brand of Lomustine

C9H16ClN3O2

CCNU

CCNU [Chloroethyl nitrosoureas]

CCRIS 860

CHEMBL514

CID3950

CINU

Cecenu

CeeNU

CeeNU (TN)

CeeNU, CCNU, Lomustine

Chloroethylcyclohexylnitrosourea

Cyclohexyl chloroethyl nitrosourea

D00363

D008130

DB01206

EINECS 235-859-2

FT-0083566

HMS2090A17

HSDB 6519

I06-0087

ICIG 1109

LS-728

Lomustina

Lomustina [INN-Spanish]

Lomustine (USAN/INN)

Lomustine [USAN:BAN:INN]

Lomustine medac Brand

Lomustinum

Lomustinum [INN-Latin]

MolPort-001-768-818

N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea

N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea

NCGC00167466-01

NCI-C04740

NCI60_041743

NCIMech_000220

NPFAPI-06

NSC 79037

NSC-79037

NSC79037

OR5087

RB 1509

Rhone Poulenc Rorer Brand of Lomustine

Rhone-Poulenc Rorer Brand of Lomustine

S1840_Selleck

SRI 2200

UNII-7BRF0Z81KG

WLN: L6TJ AMVNNO&2G

ZINC03831006

lomustine

medac Brand of Lomustine

Temozolomide

approved, investigational

Phase 3, Phase 2, Phase 1

693

85622-93-1

5394

Synonyms:

3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide

3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide

3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide

3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide

3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide

3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide

3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide

3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide

3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide

8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one

8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one

85622-93-1

AC-758

AC1L1K9B

BIDD:GT0204

BRN 5547136

Bio-0147

C047246

C6H6N6O2

CCRG 81045

CCRG-81045

CCRIS 8996

CHEBI:153686

CHEMBL810

CID5394

CPD000466338

D06067

DB00853

Essex brand of temozolomide

HMS2051O12

HMS2090B08

I06-0149

I14-1943

LS-80558

M B 39831

M & B 39831

M&B 39831

M&B-39831

M-39831

MB 39831

MLS000759447

MLS001424028

MLS002701861

Methazolastone

NCGC00167429-01

NCGC00167429-02

NCI60_003316

NSC 362856

NSC-362856

NSC362856

SAM001246636

SMR000466338

STK623541

Sch 52365

Sch-52365

Schering brand of temozolomide

Schering-Plough brand of temozolomide

TL8005593

TMZ

TMZ-Bioshuttle

Temodal

Temodal (TN)

Temodar

Temozolamide

Temozolodida

Temozolodida [Spanish]

Temozolomid

Temozolomida

Temozolomide (JAN/USAN/INN)

Temozolomide [INN:BAN]

Temozolomidum

Temozolomidum [Latin]

Témozolomide

UNII-YF1K15M17Y

ZINC01482184

m & b 39831

temozolomide

Carmustine

approved

Phase 3, Phase 2, Phase 1

212

154-93-8

2578

Synonyms:

1,3-BIS(CHLOROETHYL)-1-NITROSOUREA

1,3-Bis(.beta.-chloroethyl)-1-nitrosourea

1,3-Bis(2-chloroethyl)-1-nitrosourea

1,3-Bis(2-chloroethyl)nitrosourea

1,3-Bis(beta-chloroethyl)-1-nitrosourea

154-93-8

AC-10563

AC1L1DZQ

AI3-52216

BCNU

BCNU [Chloroethyl nitrosoureas]

BRN 2049744

Becenum

Becenun

Bi CNU

BiCNU

BiCNU (TN)

Bicnu (tn)

Bio-0118

Bis(2-chloroethyl)1-nitrosourea

Bis(2-chloroethyl)nitrosourea

Bis(chloroethyl)nitrosourea

Bis-N,N'-(chloroethyl)nitrosourea

Bischlorethylnitrosourea

Bischlorethylnitrosurea

Bischloroethyl nitrosourea

Bischloroethyl nitrosourea [Chloroethyl nitrosoureas]

Bischloroethylnitrosourea

C 0400

C0400_SIGMA

C5H11Cl2N3O2

CCRIS 810

CHEBI:3423

CHEMBL513

CID2578

Carmubris

Carmustin

Carmustina

Carmustina [INN-Spanish]

Carmustine

Carmustine (USAN/INN)

Carmustine [USAN:INN:BAN]

Carmustinum

Carmustinum [INN-Latin]

D002330

D00254

DB00262

DTI 015

DivK1c_000835

EINECS 205-838-2

EU-0100188

FDA 0345

FIVB

FT-0083563

Gliadel

Gliadel Wafer

Gliadel, BCNU, NSC-409962, Becenun, Carmustine

HMS2092J22

HMS502J17

I14-11976

IDI1_000835

KBio1_000835

KBio2_000745

KBio2_003313

KBio2_005881

KBioGR_001296

KBioSS_000745

LS-890

Lopac-C-0400

Lopac0_000188

MLS001333962

MolPort-003-665-505

N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA

N,N'-Bis(2-chloroethyl)-N-nitrosourea

NCGC00015204-01

NCGC00015204-02

NCGC00015204-06

NCGC00093665-01

NCGC00093665-02

NCGC00093665-03

NCGC00093665-04

NCI-C04773

NCI60_003931

NINDS_000835

NSC 409962

NSC-409962

NSC409962

Nitrumon

Prestwick_997

S1521_Selleck

SK 27702

SMR000058426

SRI 1720

STK624770

Spectrum4_000888

Spectrum5_000920

Spectrum_000265

UNII-U68WG3173Y

WLN: ONN2GVM2G

ZINC03830387

bis-chloroethylnitrosourea

carmustine

carmustine in ethanol

Morphine

approved, investigational

Phase 3

960

57-27-2

5288826

Synonyms:

(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol

(-)-Heroin hydrochloride

(-)-Morphine

(-)Morphine sulfate

(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol

(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol

(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol

(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol

(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol

(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol

(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol

(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol

(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL

(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol

(−)-morphine

17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol

4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol

4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol

47106-99-0

57-27-2

6211-15-0 (sulfate (2:1) (salt) pentahydrate)

64-31-3

64-31-3 (sulfate (2:1) (salt) anhydrous)

7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol

7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol

8053-16-5

85201-37-2

Apokyn

Astramorph PF

Avinza

BIDD:GT0147

C01516

CCRIS 5762

CHEBI:17303

CHEMBL70

CID5288826

Cube juice

D-(-)-Morphine

DB00295

DEA No. 9300

DepoDur

Depodur

Diacetylmorphine hydrochloride

Diamorphine hydrochloride

Dolcontin

Dreamer

Dulcontin

Duramorph PF

Duromorph

EINECS 200-320-2

Epimorph

HSDB 2134

Hard stuff

Heroin hydrochloride

Heroine hydrochloride

Hocus

Infumorph

Kadian

LS-91748

M-Eslon

M.O.S

MOI

MORPHINE SULFATE

MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE

MS Contin

MS/L

MS/S

MSIR

Meconium

MolPort-003-849-273

Morfina

Morfina [Italian]

Morphia

Morphin

Morphin [German]

Morphina

Morphina [Italian]

Morphine Extra-Forte

Morphine Forte

Morphine H.P

Morphine Sulfate

Morphine [BAN]

Morphinism

Morphinum

Morphitec

Morphium

Morpho

Moscontin

Ms Contin

Ms Emma

NSC11441

Nepenthe

O,O'-Diacetylmorphine hydrochloride

OMS Concentrate

Oramorph SR

Ospalivina

RMS

RMS Uniserts

Rescudose

Roxanol

Roxanol 100

Roxanol UD

SDZ 202-250

SDZ202-250

Statex

Statex Drops

Statex SR

UNII-76I7G6D29C

Unkie

l-Morphine

morfina

morphine

nchembio.317-comp1

nchembio.64-comp1

Methylphenidate

approved, investigational

Phase 3

373

113-45-1

4158

Synonyms:

.alpha.-Phenyl-2-piperidineacetic acid methyl ester

113-45-1

2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester

2-Piperidineacetic acid, alpha-phenyl-, methyl ester

298-59-9 (hydrochloride)

4311/B Ciba

AC1L1HJM

C 4311

C07196

CHEBI:6887

CHEMBL796

CID4158

Calocain

Centedein

Centedrin

Centedrine

Centredin

Concerta

D-Methylphenidate HCl

D04999

DB00422

DB06701

DEA No. 1724

Daytrana

Daytrana (TN)

EINECS 204-028-6

Focalin

Focalin XR

HSDB 3126

L001307

LS-565

METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)

MPH

Meridil

Metadate

Metadate CD

Metadate ER

MethyPatch

Methyl (2-phenyl-2-(2-piperidyl)acetate)

Methyl alpha-phenyl-alpha-(2-piperidyl)acetate

Methyl alpha-phenyl-alpha-2-piperidinylacetate

Methyl phenidate

Methyl phenidyl acetate

Methyl phenidylacetate

Methylfenidan

Methylin

Methylin ER

Methylofenidan

Methylphen

Methylphenidan

Methylphenidate

Methylphenidate (USAN/INN)

Methylphenidate HCl

Methylphenidate [INN:BAN]

Methylphenidate hydrochloride

Methylphenidatum

Methylphenidatum [INN-Latin]

Methylphenidylacetate hydrochloride

Methypatch

Metilfenidat hydrochloride

Metilfenidato

Metilfenidato [INN-Spanish]

Metilfenidato [Italian]

MolPort-001-779-620

NCI-C56280

PMS-Methylphenidate

Phenidylate

Plimasine

Riphenidate

Ritalin

Ritalin LA

Ritalin SR

Ritalin hydrochloride

Ritalin-SR

Ritaline

Ritcher Works

Ritcher works

Tsentedrin

UNII-207ZZ9QZ49

alpha-Phenyl-2-piperidineacetic acid methyl ester

alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester

d-methylphenidate HCl

methyl 2-phenyl-2-piperidin-2-ylacetate

methyl phenyl(piperidin-2-yl)acetate

methylphenidate

nchembio.2007.55-comp28

Fentanyl

approved, illicit, investigational, vet_approved

Phase 3

773

437-38-7

3345

Synonyms:

1-Phenethyl-4-(N-phenylpropionamido)piperidine

1-Phenethyl-4-N-propionylanilinopiperidine

1-phenethyl-4-N-propionylanilinopiperidine

437-38-7

5-22-08-00049 (Beilstein Handbook Reference)

80832-90-2

990-73-8 (citrate)

AC1L1FQ2

Actiq

BIDD:GT0555

BRN 0494484

CHEBI:119915

CHEMBL596

CID3345

D00320

DB00813

Duragesic

Duragesic (TN)

Duragesic-100

Duragesic-12

Duragesic-25

Duragesic-50

Duragesic-75

Durogesic

EINECS 207-113-6

Fentanest

Fentanil

Fentanil [DCIT]

Fentanila

Fentanila [INN-Spanish]

Fentanilo

Fentanyl

Fentanyl (JAN/USAN/INN)

Fentanyl CII

Fentanyl [INN:BAN]

Fentanyl citrate

Fentanyl-100

Fentanyl-12

Fentanyl-25

Fentanyl-50

Fentanyl-75

Fentanylum

Fentanylum [INN-Latin]

HSDB 3329

IONSYS

JNS020QD

L001275

LS-124439

Matrifen

MolPort-003-847-369

N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide

N-(1-Phenethyl-4-piperidyl)propionanilide

N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide

N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide

N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide

N-(1-phenethyl-4-piperidyl)propionanilide

N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide

N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide

N-Phenethyl-4-(N-propionylanilino)piperidine

N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide

N-phenethyl-4-(N-propionylanilino)piperidine

N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide

N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide

NCGC00168252-01

Nasalfent

Oprea1_152073

Oprea1_207148

PDSP1_000860

PDSP2_000846

Pentanyl

Phentanyl

Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)

R 4263

Rapinyl

Sentonil

Sublimase

Sublimaze

UNII-UF599785JZ

fentanyl

Vincristine

approved, investigational

Phase 3, Phase 1, Phase 2

904

2068-78-2, 57-22-7

5978

Synonyms:

22-Oxovincaleukoblastin

22-Oxovincaleukoblastine

28379-27-3

57-22-7

AC1L1LJC

C07204

C46H56N4O10

CCRIS 5763

CHEBI:28445

CID5978

D08679

DB00541

EINECS 200-318-1

HMS2090E19

HSDB 3199

Indole alkaloid

LCR

LS-228

Leurocristine

Lilly 37231 (1:1 sulfate salt)

Liposomal Vincristine

Marqibo

NCGC00163700-01

NCI-C04864

NCI60_026703

NSC-67574

Onco TCS

Oncovin

Oncovin (1:1 sulfate salt)

Oncovine

Tecnocris

Tecnocris (TN)

UNII-5J49Q6B70F

VCR

VIN

Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine

Vincasar

Vincasar (1:1 sulfate salt)

Vincasar PFS

Vincrex

Vincrex (1:1 sulfate salt)

Vincristin

Vincristina

Vincristina [DCIT]

Vincristine (INN)

Vincristine Sulfate

Vincristine Sulfate PFS

Vincristine [INN:BAN]

Vincristinum

Vincristinum [INN-Latin]

Vincrstine

Vincrystine

Vinkristin

Z-D-Val-Lys(Z)-OH

vincristine

Donepezil

approved

Phase 3, Phase 2

280

120014-06-4

3152

Synonyms:

( inverted exclamation markA)-E 2020

1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine

120014-06-4

2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one

2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one

AB1004836

AC-6969

AC1L1FAE

AKOS000277311

Aricept

Aricept ODT

C24H29NO3

CHEBI:53289

CHEMBL502

CID3152

D07869

DB00843

Domepezil

Donaz

Donaz (TN)

Donepezil

Donepezil (INN)

Donepezil [INN:BAN]

Donepezil hydrochloride

Donepezilo

Donepezilum

Eranz

I06-0343

KBio2_002144

KBio2_004712

KBio2_007280

KBioSS_002144

LS-81819

MolPort-000-881-588

MolPort-003-847-014

NCGC00167537-01

Oprea1_188452

Spectrum5_001662

Spectrum_001664

TL8000531

UNII-8SSC91326P

Leflunomide

approved, investigational

Phase 3

75706-12-6

3899

Synonyms:

210165-51-8

4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl

4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl)

5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide

5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide

5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide)

5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide

5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide

5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide

5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide

75706-12-6

A77 1486

AB00052389

AC-6796

AC1L1GYK

AC1Q2EVA

AKOS000265193

AP-501/42475599

Arava

Arava (TN)

Arava, Leflunomide

Aventis Behring Brand of Leflunomide

Aventis Brand of Leflunomide

Aventis Pharma Brand of Leflunomide

BIDD:PXR0189

BPBio1_000930

BRD-K78692225-001-03-9

BSPBio_000844

C045463

C07905

CAS-75706-12-6

CHEBI:6402

CHEMBL960

CID3899

D00749

DB01097

DivK1c_000916

EU-0100649

HMS1570K06

HMS1922M06

HMS2090O12

HMS502N18

HSDB 7289

HWA 486

HWA-486

Hoechst Brand of Leflunomide

I06-2131

IDI1_000916

KBio1_000916

KBio2_000802

KBio2_003370

KBio2_005938

KBioSS_000802

L 5025

L5025_SIGMA

LS-86580

Leflunomid

Leflunomida

Leflunomida [INN-Spanish]

Leflunomide

Leflunomide (JAN/USAN/INN)

Leflunomide [USAN:INN]

Leflunomidum

Leflunomidum [INN-Latin]

Lefunomide

Lefunomide [INN-Spanish]

Lefunomide [Inn-Spanish]

Lopac-L-5025

Lopac0_000649

MLS-0003109.0001

MLS000069648

MLS001076267

MolPort-002-345-613

N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide

N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide

NCGC00015610-01

NCGC00015610-02

NCGC00015610-03

NCGC00015610-07

NCGC00015610-12

NCGC00022625-03

NCGC00022625-04

NCGC00022625-05

NCGC00022625-06

NCGC00022625-07

NCGC00022625-08

NINDS_000916

NSC677411

Prestwick0_000772

Prestwick1_000772

Prestwick2_000772

Prestwick3_000772

Prestwick_87

RS-34821

S1247_Selleck

SMR000058209

SPBio_002783

SPECTRUM1503927

SU 101

SU 101 (pharmaceutical)

SU-101

SU101

Spectrum5_000850

Spectrum_000322

TL8005179

UNII-G162GK9U4W

ZINC00004840

alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-P-toluidide

alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide

leflunomide

lefunamide

Isotretinoin

approved

Phase 3, Phase 2, Phase 1

118

4759-48-2

5538, 5282379

Synonyms:

(13-cis)-Retinoate

(13-cis)-Retinoic acid

(13cis)-retinoic acid

(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid

(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid

(7E,9E,11E,13Z)-retinoic acid

(7e,9e,11e,13Z)-Retinoic acid

13 Cis-Retinoic Acid

13 cis retinoic acid

13-RA

13-cis RA

13-cis retinoic acid

13-cis-Retinoate

13-cis-Retinoic acid

13-cis-Vitamin A acid

13-cis-Vitamin a acid

3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid

4-09-00-02388 (Beilstein Handbook Reference)

4759-48-2

97950-17-9

AC-15388

AC1NQZZ4

Accutane

Accutane (TN)

Ambap302-79-4

Amnesteem

BML2-E07

BPBio1_000080

BRD-K76723084-001-05-9

BRN 1885770

BSPBio_000072

BSPBio_001331

BSPBio_003345

CCRIS 4286

CHEBI:6067

CHEMBL547

CID5282379

CIP-Isotretinoin

CPD000471891

Claravis

D00348

D015474

EINECS 225-296-0

EU-0101081

HMS1361C13

HMS1568D14

HMS1791C13

HMS1921D08

HMS1989C13

HMS2092N07

HSDB 3929

IDI1_033801

Isotane

Isotretinoin

Isotretinoin (USP)

Isotretinoin Retinoic acid

Isotretinoin Zinc Salt, 13 cis Isomer

Isotretinoin Zinc Salt, 13-cis-Isomer

Isotretinoin [USAN:BAN:INN]

Isotretinoin [USAN:INN:BAN]

Isotretinoina

Isotretinoine

Isotretinoine [INN-French]

Isotretinoino

Isotretinoino [INN-Spanish]

Isotretinoinum

Isotretinoinum [INN-Latin]

Isotrex

LMPR01090021

LS-143465

Lopac0_001081

MLS001074662

MolPort-003-666-394

NCGC00094358-01

NCGC00094358-02

NCGC00094358-03

NCGC00094358-04

NCGC00094358-05

NCGC00094358-06

NCGC00094358-07

NCGC00094358-08

NCGC00094358-09

NCGC00094358-13

Neovitamin A acid

Neovitamin a acid

Prestwick2_000256

Prestwick3_000256

Prestwick_642

R 3255

R3255_SIGMA

Retinoate

Retinoic acid

Ro 4 3780

Ro 4-3780

Ro 43780

Ro-4-3780

Ro-43780

Roaccutan

Roaccutane

Roacutan

SAM002548955

SMR000471891

SPECTRUM1502013

Sotret

Sotret (TN)

Spectrum5_001795

Spectrum5_001937

Teriosal

UNII-EH28UP18IF

cis-RA

cis-Retinoate

cis-Retinoic acid

isotretinoino

Dopamine

approved

Phase 3, Phase 1

3759

51-61-6, 62-31-7

681

Synonyms:

(3H)-Dopamine

.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride

.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane

1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)

1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride

1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium

153C5321-5FEE-4B0B-8925-F388F0EEEBD1

2-(3,4-Dihydroxyphenyl)ethylamine

2-(3,4-dihydroxyphenyl)ethylamine

2-benzenediol

3,4-Dihydroxyphenethylamine

3,4-Dihydroxyphenethylamine hydrochloride

3,4-Dihydroxyphenylethylamine

3,4-dihydroxyphenethylamine

3-Hydroxtyramine

3-Hydroxytyramine

3-Hydroxytyramine Hydrobromide

3-Hydroxytyramine hydrochloride

4-(2-Aminoethyl)-1,

4-(2-Aminoethyl)-1,2-benzenediol

4-(2-Aminoethyl)-1,2-bezenediol

4-(2-Aminoethyl)-Pyrocatechol

4-(2-Aminoethyl)benzene-1,2-diol

4-(2-Aminoethyl)catechol

4-(2-Aminoethyl)pyrocatechol

4-(2-Aminoethyl)pyrocatechol hydrochloride

4-(2-aminoethyl)-pyrocatechol

50444-17-2

51-61-6

62-31-7 (HYDROCHLORIDE)

AC1L19S5

AC1Q54AX

AC1Q54AY

AKOS003790978

ASL 279

BIDD:ER0506

BPBio1_001123

BSPBio_001932

Biomol-NT_000001

C03758

CHEBI:18243

CHEMBL59

CID681

D07870

DB00988

Deoxyepinephrine

DivK1c_000780

Dopamin

Dopamina

Dopamina [INN-Spanish]

Dopamine

Dopamine (INN)

Dopamine (USAN)(*hydrochloride*)

Dopamine [INN:BAN]

Dopaminum

Dopaminum [INN-Latin]

Dopastat

Dophamine

Dynatra

EINECS 200-110-0

HSDB 3068

Hydroxytyramin

Hydroxytyramine

IDI1_000780

IP 498

Intropin

Intropin [*hydrochloride*]

KBio1_000780

KBio2_001492

KBio2_002388

KBio2_002484

KBio2_004060

KBio2_004956

KBio2_005052

KBio2_006628

KBio2_007524

KBio2_007620

KBio3_001152

KBio3_002867

KBio3_002962

KBioGR_001129

KBioGR_002388

KBioGR_002484

KBioSS_001492

KBioSS_002393

KBioSS_002491

KW-3-060

L-DOPAMINE

L000232

LDP

LS-159

Lopac-H-8502

Lopac0_000586

Medopa (TN)

MolPort-001-641-000

NCGC00015519-01

NCGC00015519-08

NCGC00096050-01

NCGC00096050-02

NCGC00096050-03

NCGC00096050-04

NCGC00096050-05

NINDS_000780

NSC 173182

NSC169105

NSC173182

Oprea1_088821

Oxytyramine

Pyrocatechol, 4-(2-aminoethyl)- (8CI)

Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride

Revimine

Revivan

SPBio_001205

SPECTRUM1505155

ST048774

STK301601

Spectrum2_001023

Spectrum3_000406

Spectrum4_000525

Spectrum5_000945

Spectrum_001012

UNII-VTD58H1Z2X

UPCMLD0ENAT5885989:001

a-(3,4-Dihydroxyphenyl)-b-aminoethane

alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane

cMAP_000036

cMAP_000065

dopamine

hydroxytyramine

intropin

m-Hydroxytyramine hydrochloride

nchembio.105-comp9

nchembio.107-comp4

nchembio.284-comp1

nchembio.78-comp16

nchembio.89-comp3

nchembio705-8

nchembio801-comp8

Cyproheptadine

approved

Phase 3

129-03-3

2913

Synonyms:

1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine

1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine

1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine

129-03-3

4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine

4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine

4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine

4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene

4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine

4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine

4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine

4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine

41354-29-4

5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene

5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene

5-20-08-00500 (Beilstein Handbook Reference)

AC1L1ER8

AKOS004119847

Axoprol

BIDD:GT0324

BPBio1_000096

BPBio1_000155

BRD-K28143534-001-01-4

BRD-K28143534-003-03-6

BRN 1685976

BSPBio_000086

Biomol-NT_000131

C06935

CAS-969-33-5

CCRIS 5232

CHEBI:4046

CHEMBL516

CID2913

CYPROHEPTADINE

Ciproheptadina

Ciproheptadina [INN-Spanish]

Ciprovit

Ciprovit (TN)

Cypoheptadine

Cyproheptadiene

Cyproheptadin

Cyproheptadine

Cyproheptadine (INN)

Cyproheptadine Hcl

Cyproheptadine [INN:BAN]

Cyproheptadinum

Cyproheptadinum [INN-Latin]

D07765

DB00434

Dibenzosuberonone/Cyproheptadine

Dihexazin

Dronactin

EINECS 204-928-9

Eiproheptadine

Glutodina

HMS2090P20

HSDB 3048

L001016

LS-114933

Lopac-C-6022

Lopac0_000246

MK 141

MolPort-002-507-777

NCGC00015252-01

NCGC00015252-02

NCGC00015252-03

NCGC00015252-09

NCGC00024293-02

NCGC00024293-04

NCGC00024293-05

Oprea1_498140

PDSP1_001229

PDSP2_001213

Periactin

Periactine

Periactinol

Prestwick0_000103

Prestwick1_000103

Prestwick2_000103

Prestwick3_000103

SPBio_002025

STK802098

Tocris-0996

UNII-2YHB6175DO

Viternum

nchembio.559-comp10

Histamine

approved

Phase 3

1034

75614-87-8, 51-45-6

774

Synonyms:

.beta.-Imidazolyl-4-ethylamine

1H-Imidazole-4-ethanamine

1H-Imidazole-5-ethanamine

1avn

1qft

2-(1H-Imidazol-4-yl)ethanamine

2-(1H-Imidazol-4-yl)ethylamine

2-(1H-Imidazol-5-yl)ethanamine

2-(1H-Imidazol-5-yl)ethylamine

2-(1H-imidazol-4-yl)ethan-1-amine

2-(1H-imidazol-5-yl)ethanamine

2-(3H-Imidazol-4-yl)-ethylamine

2-(4-Imidazolyl)ethanamine

2-(4-Imidazolyl)ethylamine

2-Imidazol-4-yl-Ethylamine

2-Imidazol-4-ylethylamine

2-[4-Imidazolyl]ethylamine

4-(2-Aminoethyl)-1H-imidazole

4-(2-Aminoethyl)imidazole

4-Imidazoleethylamine

5-Imidazoleethylamine

51-45-6

53290_FLUKA

64422-25-9

924364-91-0

AC-13185

AC1L19ZT

AC1Q54BV

AC1Q54BW

AKOS000274386

ALBB-005968

BCBcMAP01_000250

BSPBio_001117

BSPBio_002124

Bio1_000487

Bio1_000976

Bio1_001465

Bio2_000389

Bio2_000869

C00388

CCRIS 6535

CHEBI:18295

CHEMBL90

CID774

D08040

DivK1c_000308

EINECS 200-100-6

Eramin

Ergamine

Ergotidine

F411C768-A159-4FC0-A195-291A08BB03AA

Free histamine

H7125_SIGMA

HMS1362G19

HMS1792G19

HMS1990G19

HSDB 3338

HSM

Histamine

Histamine (DCF)

Histamine Base

Histamine [USAN]

Histamine, Free Base

Histaminum

Histaminum (TN)

IDI1_000308

IDI1_002144

Imidazole-4-ethylamine

Istamina

Istamina [Italian]

KBio1_000308

KBio2_000457

KBio2_001325

KBio2_003025

KBio2_003893

KBio2_005593

KBio2_006461

KBio3_000853

KBio3_000854

KBio3_001344

KBioGR_000457

KBioGR_001580

KBioSS_000457

KBioSS_001325

L-Histamin base

L-Histamine

L-histamine

L000292

LS-75835

Lopac-H-7250

Lopac0_000595

MLS000069447

MolPort-001-785-597

MolPort-002-042-264

NCGC00015513-01

NCGC00015513-08

NCGC00093371-02

NCGC00093371-03

NCGC00093371-04

NCGC00093371-05

NINDS_000308

NSC 33792

NSC33792

SDCCGMLS-0066601.P001

SMP1_000151

SMR000059091

SPBio_000729

ST073926

STK346752

STOCK5S-55669

Spectrum2_000665

Spectrum3_000452

Spectrum4_000960

Spectrum5_000796

Spectrum_000845

Theramine

UNII-820484N8I3

WLN: T5M CNJ D2Z

ZERO/004089

[3H]histamine

b-Imidazolyl-4-ethylamine

beta-Aminoethylglyoxaline

beta-Aminoethylimidazole

beta-Aminothethylglyoxaline

beta-Imidazolyl-4-ethylamine

beta-aminothethylglyoxaline

bmse000744

histamine

nchembio.87-comp54

nchembio714-comp1

Histamine Phosphate

approved

Phase 3

1033

51-74-1

65513

Synonyms:

1H-Imidazole-4-ethanamine, phosphate (1:2)

2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)

4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)

4-(2-Aminoethyl)imidazole di-acid phosphate

4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate

51-74-1

53623-99-7

74-56-6

AC1L23E4

CID65513

D04445

DB00667

EINECS 200-118-4

H0147

Histamine acid phosphate

Histamine biphosphate

Histamine dihydrogen phosphate

Histamine diphosphate

Histamine phosphate (1:2)

Histamine phosphate (TN)

Histamine phosphate (USP)

Histamine phosphate [USP]

Histamine positive

Histaminum

LS-78569

UNII-QWB37T4WZZ

Tretinoin

approved, investigational, nutraceutical

Phase 3, Phase 2, Phase 1

220

302-79-4

5538

Synonyms:

(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid

.beta.-Retinoic acid

13497-05-7 (hydrochloride salt)

15-Apo-beta-caroten-15-oic acid

187175-63-9

1n4h

3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid

3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)

302-79-4

5300-03-8

56573-65-0

7005-78-9

9(Z)-Retinoic acid

9-cis-RA

A-Acido (Argentina)

A-Vitaminsyre

A-Vitaminsyre [Denmark]

AC-6824

AC1L9GWO

AC1Q1J2J

AGN 100335

AGN 192013

AKOS000280845

ALRT 1057

AT-RA

ATRA

Aberel

Aberela

Aberela [Norway]

Accutane Roche

Acid A Vit (Belgium, Netherlands)

Acid, Retinoic

Acid, Vitamin A

Acid, all-trans-Retinoic

Acid, beta-all-trans-Retinoic

Acid, trans-Retinoic

Acide retinoique (French) (DSL)

Acide retinoique (french) (dsl)

Acnavit

Acnavit [Denmark]

Airol

Aknefug

Aknoten

Alitretinoin

All Trans Retinoic Acid

All Trans-Retinoic Acid

All-trans Retinoic Acid

Alltrans-retinoic acid

Amnesteem

Atra-IV

Atragen

Atralin

Avita (TN)

Avita Gel

Avitoin

Avitoin [Norway]

BAL4079

BIDD:GT0483

BIDD:PXR0081

BML2-E05

BPBio1_000082

BRN 2057223

BSPBio_000074

BSPBio_001500

Betarretin

C00777

CCRIS 3294

CCRIS 7098

CHEBI:15367

CHEMBL38

CID444795

CPD000058245

Claravis

Cordes VAS [Germany]

Cordes vas

D00094

D014212

DB00523

DB00755

DB00982

Dermairol

EINECS 206-129-0

EU-0101061

Effederm

Effederm [France]

Epi-aberel

Eudyna

HMS1361K22

HMS1568D16

HMS1791K22

HMS1921D14

HMS1989K22

HMS2089D20

HMS2092N11

HMS502N05

HSDB 2169

HSDB 7186

I04-0008

I14-2351

IDI1_000903

IDI1_033970

Isotretinoin Retinoic acid

L000833

LGD 100057

LMPR01090019

LS-1154

Lopac0_001061

Lsotretinoin

MLS000028588

MLS001076515

MLS002207234

MLS002222211

MolPort-000-883-857

NCGC00017280-06

NCGC00017280-17

NCGC00021808-04

NCGC00021808-05

NCGC00021808-06

NCGC00021808-07

NCGC00021808-09

NCGC00021808-14

NCGC00021808-15

NSC 122758

NSC-122758

NSC122758

Nexret

PDT-002-002

Panretin Gel

Panretyn

Potassium Salt, Tretinoin

Prestwick2_000257

Prestwick3_000257

Prestwick_424

R 2625

R0064

R2625_SIGMA

REA

RETINOIC ACID, ALL TRANS

RETINOIC acid

Renova

Renova (TN)

Retacnyl

Retin A

Retin A (TN)

Retin-A

Retin-A Micro

Retin-a

Retinoate

Retinoic acid

Retinoic acid, all-trans- (8CI)

Retinova

Retionic Acid

Retionic acid

Retisol-A

Retisol-a

Ro 1-5488

S1653_Selleck

SAM002264647

SMR000058245

SPECTRUM1502016

SR-01000000239

SR-01000000239-14

ST057075

Salt, Tretinoin Potassium

Salt, Tretinoin Sodium

Salt, Tretinoin Zinc

Sodium Salt, Tretinoin

Solage

Sotret

Spectrum5_001746

Spectrum5_001933

Stieva-A

Stieva-a

Stieva-a Forte

TRETINON

Tretin M

Tretin m

Tretinoin

Tretinoin (JAN/USP/INN)

Tretinoin (TN)

Tretinoin 0.1% cream or placebo

Tretinoin Potassium Salt

Tretinoin Sodium Salt

Tretinoin Zinc Salt

Tretinoin [USAN:INN:BAN]

Tretinoin/All-Trans Retinoic Acid

Tretinoina

Tretinoina [INN-Spanish]

Tretinoine

Tretinoine (french) (einecs)

Tretinoine [INN-French]

Tretinoino

Tretinoino [INN-Spanish]

Tretinoinum

Tretinoinum [INN-Latin]

Tri-Luma

Trétinoïne

UNII-1UA8E65KDZ

UNII-5688UTC01R

UPCMLD-DP097

Vesanoid

Vesanoid (TN)

Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin

Vesnaroid

Vitamin A acid

Vitinoin

WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1

WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1

Zinc Salt, Tretinoin

[3H]Retinoic acid

all trans-Retinoic acid

all-(E)-Retinoic acid

all-(e)-Retinoic acid

all-trans-Retinoic acid

all-trans-Tretinoin

all-trans-Vitamin A acid

all-trans-Vitamin A1 acid

all-trans-Vitamin a acid

all-trans-Vitamin a1 acid

all-trans-b-Retinoic acid

all-trans-beta-Retinoic acid

b-Retinoic acid

beta all trans Retinoic Acid

beta-Ra

beta-Retinoic Acid

beta-Retinoic acid

beta-all-trans-Retinoic acid

bmse000562

nchembio.154-comp2

trans Retinoic Acid

trans-Retinoic acid

tretinoin

tretinoin liposome

tretinoine (French) (EINECS)

Veliparib

investigational

Phase 2, Phase 3, Phase 1

912444-00-9

11960529

Synonyms:

(2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium

2-((2R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide

ABT 888

ABT-888

veliparib

Peripheral Nervous System Agents

Phase 3, Phase 2, Phase 1

22776

Angiogenesis Inhibitors

Phase 3, Phase 2, Phase 1

4143

Alkylating Agents

Phase 3, Phase 2, Phase 1

4694

Angiogenesis Modulating Agents

Phase 3, Phase 2, Phase 1

4072

Analgesics

Phase 3, Phase 2, Phase 1

11287

Keratolytic Agents

Phase 3, Phase 1, Phase 2

420

Antirheumatic Agents

Phase 3, Phase 1, Phase 2

10627

Immunosuppressive Agents

Phase 3, Phase 2, Phase 1

12770

Central Nervous System Depressants

Phase 3, Phase 2, Phase 1

12806

Photosensitizing Agents

Phase 3, Phase 2, Phase 1

476

Ether

Phase 3

Dermatologic Agents

Phase 3, Phase 1, Phase 2

5674

Dihematoporphyrin Ether

Phase 3, Phase 1

Antimitotic Agents

Phase 3, Phase 1, Phase 2

5498

Antineoplastic Agents, Alkylating

Phase 3, Phase 2, Phase 1

4474

Antineoplastic Agents, Phytogenic

Phase 3, Phase 2, Phase 1

5420

Narcotics

Phase 3

3486

Liver Extracts

Phase 3, Phase 2, Phase 1

3868

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2, Phase 3, Phase 1

309

Mitogens

Phase 3, Phase 1, Phase 2

1526

Immunoglobulins

Phase 3, Phase 2, Phase 1

6045

Gastrointestinal Agents

Phase 3, Phase 2, Phase 1

8109

Endothelial Growth Factors

Phase 3, Phase 2, Phase 1

362

Epoetin alfa

Phase 3

645

113427-24-0

Analgesics, Opioid

Phase 3

3091

Anesthetics, Intravenous

Phase 3

2406

Central Nervous System Stimulants

Phase 3, Phase 2, Phase 1

2132

Adjuvants, Anesthesia

Phase 3

1588

O(6)-benzylguanine

Phase 3, Phase 2, Phase 1

Neurotransmitter Agents

Phase 3, Phase 2, Phase 1

17734

Interventional clinical trials:

(show top 50) (show all 454)

id	Name	Status	NCT ID	Phase
1	Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas	Unknown status	NCT00003788	Phase 3
2	S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma	Completed	NCT00017147	Phase 3
3	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma	Completed	NCT01480479	Phase 3
4	Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme	Completed	NCT00820963	Phase 3
5	Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme	Completed	NCT00482677	Phase 3
6	Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Completed	NCT00006353	Phase 3
7	Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme	Completed	NCT00002545	Phase 3
8	Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma	Completed	NCT00003916	Phase 3
9	SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme	Completed	NCT00003293	Phase 3
10	High Light and Low Light Dose PDT in Glioma	Completed	NCT00118222	Phase 3
11	Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma	Completed	NCT00052455	Phase 3
12	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3
13	E-MOSAIC Electronic Tool to Monitor Symptoms	Completed	NCT00477919	Phase 3
14	Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors	Completed	NCT00369785	Phase 3
15	Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma	Active, not recruiting	NCT00304031	Phase 3
16	Temozolomide (TMZ) and Radiation Therapy (RT) With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)	Active, not recruiting	NCT00884741	Phase 3
17	Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Suspended	NCT02152982	Phase 2, Phase 3
18	Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	Terminated	NCT01132547	Phase 3
19	Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors	Terminated	NCT00031798	Phase 3
20	Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas	Withdrawn	NCT00003564	Phase 3
21	Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma	Unknown status	NCT01124539	Phase 2
22	Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme	Unknown status	NCT00883298	Phase 2
23	Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma	Unknown status	NCT00936052	Phase 2
24	Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas	Unknown status	NCT01721577	Phase 1, Phase 2
25	Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Unknown status	NCT00486603	Phase 1, Phase 2
26	Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Unknown status	NCT00006460	Phase 1, Phase 2
27	Antineoplaston Therapy in Treating Patients With Glioblastoma Multiforme	Unknown status	NCT00003456	Phase 2
28	131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma	Unknown status	NCT00114309	Phase 2
29	Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas	Unknown status	NCT00492687	Phase 2
30	Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme	Unknown status	NCT00054496	Phase 2
31	Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Unknown status	NCT00047294	Phase 2
32	Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme	Unknown status	NCT00014105	Phase 1, Phase 2
33	Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	Unknown status	NCT00006656	Phase 2
34	Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma	Unknown status	NCT00045110	Phase 1, Phase 2
35	Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma	Unknown status	NCT00003176	Phase 2
36	A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain	Unknown status	NCT01403311	Phase 2
37	Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma	Unknown status	NCT00047281	Phase 2
38	Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm	Unknown status	NCT00009854	Phase 1, Phase 2
39	Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma	Completed	NCT00525525	Phase 2
40	Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas	Completed	NCT00612339	Phase 2
41	Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma	Completed	NCT00335764	Phase 1, Phase 2
42	Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas	Completed	NCT00597402	Phase 2
43	Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients	Completed	NCT00402116	Phase 1, Phase 2
44	Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors	Completed	NCT00187486	Phase 2
45	Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma	Completed	NCT00433381	Phase 2
46	Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma	Completed	NCT00305864	Phase 1, Phase 2
47	Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme	Completed	NCT00979017	Phase 2
48	Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme	Completed	NCT00165477	Phase 2
49	AMG 102 and Avastin for Recurrent Malignant Glioma	Completed	NCT01113398	Phase 2
50	Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma	Completed	NCT00028795	Phase 2

Search NIH Clinical Center for Gliosarcoma

Cochrane evidence based reviews: gliosarcoma

Genetic Tests for Gliosarcoma

Anatomical Context for Gliosarcoma

Sources:
³⁶MalaCards
See all MalaCards sources

MalaCards organs/tissues related to Gliosarcoma:

³⁶

Brain, Bone, T cells, Bone marrow, Prostate, Liver, Spinal cord

Publications for Gliosarcoma

Sources:
⁵⁷PubMed
See all MalaCards sources

Articles related to Gliosarcoma:

(show top 50) (show all 348)

id	Title	Authors	Year
1	Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. (26725096)	Zhang G.... Wang Y.	2016
2	Primary Gliosarcoma of the Optic Nerve: A Unique Adult Optic Pathway Glioma. (27792048)	Cimino P.J.... Keene C.D.	2016
3	Evaluation of Antitumor Activity of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid in Animal Models of Breast Tumor and Gliosarcoma. (27130721)	Rocha T.G.... Tavitian B.	2016
4	Temporal Lobe Gliosarcoma After Gamma Knife Radiosurgery for Vestibular Schwannoma. (27309712)	Kapurch J.R.... Link M.J.	2016
5	Dural and osteolytic sarcomatoid relapse of a secondary gliosarcoma with tryptase immunoreactivity. (26784965)	Calderon-GarcidueA+as A.L.... Bielle F.	2016
6	Gliosarcoma with Primary Skull Base Invasion. (28053799)	Nguyen Q.D.... van Gompel J.J.	2016
7	Metastatic Gliosarcoma: Cytopathologic Characteristics with Histopathologic Correlations. (27584833)	Lee J.... Ali S.Z.	2016
8	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. (27231756)	Patel D.... Markert J.	2016
9	Gliosarcoma with a primitive neuroectodermal tumour component. (27772848)	Green C.... Robbins P.	2016
10	A Stable Secondary Gliosarcoma with Extensive Systemic Metastases: A Case Report. (27867925)	Choi T.M.... Lee K.H.	2016
11	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. (27314913)	Patel D.M.... Markert J.M.	2016
12	Concurrent Gliosarcoma and Choroid Plexus Carcinoma in a Cow. (27899174)	Ortloff A.... Illanes O.	2016
13	Gliosarcoma in the Cerebellopontine Angle with Rapid Tumor Growth and Intratumoral Hemorrhage. (27338213)	Duan H.... Sudo M.	2016
14	Gliosarcoma with smooth muscle cell differentiation: a case report. (27704522)	Bani M.A.... Kchir N.	2016
15	Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. (27169763)	Castelli J.... Noel G.	2016
16	Primary Multifocal Gliosarcoma of the Spinal Cord. (27134708)	Kumar R.M.... Finn M.	2016
17	Post-Treatment Gliosarcoma Extension into the Pterygomaxillary Fossa: Literature Review and Case Report. (27699141)	Mason A.... Burneikiene S.	2016
18	Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a gliosarcoma patient. (27523101)	Guidi M.... Sardi I.	2016
19	Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and clinical tissue imaging. (26802746)	Wu Q.... Yang C.J.	2016
20	Radiotherapy plus concomitant temozolomide in primary gliosarcoma. (27025857)	Adeberg S.... Debus J.	2016
21	Gliosarcoma: A rare variant of glioblastoma multiforme in paediatric patient: Case report and review of literature. (27672648)	Meena U.S.... Jain S.K.	2016
22	An IDH1-mutated primary gliosarcoma: case report. (27153165)	Hsieh J.K.... Sloan A.E.	2016
23	Gliosarcoma with leiomyomatous differentiation: A case report with an emphasis on histogenesis. (26881542)	Shukla S.... Ojha B.K.	2015
24	Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide. (26438548)	Mallick S.... Julka P.K.	2015
25	Brachium Pontis Gliosarcoma With Well-Differentiated Cartilaginous Tissue: A Case Report. (26496287)	Wang L.... Peng Z.	2015
26	Genetic alterations in gliosarcoma and giant cell glioblastoma. (26443480)	Oh J.E.... Ohgaki H.	2015
27	Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience. (25839013)	Kumar N.... Yadav B.S.	2015
28	Giant parietal lobe infantile gliosarcoma in a 5-year-old child. (26167224)	Savant H.V.... Mahajan V.	2015
29	An individual patient data meta-analysis on characteristics, treatments and outcomes of glioblastoma/ gliosarcoma patients with metastases outside of the central nervous system. (25860797)	Pietschmann S.... MA1ller K.	2015
30	Cell-density-dependent manifestation of partial characteristics for neuronal precursors in a newly established human gliosarcoma cell line. (25539862)	Yao P.S.... Ye Z.C.	2015
31	FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment. (26279698)	Quak E.... van der Graaf W.T.	2015
32	Therapeutic management of gliosarcoma in the temozolomide era. (25905568)	McAleer M.F.... Brown P.D.	2015
33	Cerebral gliosarcoma: Analysis of 16 patients and review of literature. (26396606)	Singh G.... Behari S.	2015
34	Gliosarcoma with neuroaxis metastases. (26621904)	Ramos R.... Almeida R.	2015
35	Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. (26354773)	Cachia D.... de Groot J.F.	2015
36	Assessing Amide Proton Transfer (APT) MRI Contrast Origins in 9A L Gliosarcoma in the Rat Brain Using Proteomic Analysis. (25622812)	Yan K.... Zhou J.	2015
37	Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: A single institutional analysis of 27 cases. (26960490)	Rath G.K.... Julka P.K.	2015
38	Long-term survival in gliosarcoma with radiation-induced meningeal sarcomas: Case report and molecular features. (26458625)	Wang Z.... Zhu X.X.	2015
39	Primary Cerebellar Gliosarcoma with Extracranial Metastases: An Orphan Differential Diagnosis. (26239018)	Ben Nsir A.... Jemel H.	2015
40	Gliosarcoma with primitive neuroectodermal, osseous, cartilage and adipocyte differentiation: a case report. (25973108)	Yao K.... Jiang T.	2015
41	Sarcomatoid carcinoma of the jejunum presenting as obscure gastrointestinal bleeding in a patient with a history of gliosarcoma. (24759341)	Alfonso Puentes N.... GarcA-a Higuera M.I.	2014
42	Recurrent gliosarcoma in pregnancy. (24900931)	GA1lA9en I.... Bayram I.	2014
43	Malignant pediatric gliosarcoma defies general survival data. (25580128)	Martin J.... Kumar Sundarraj S.	2014
44	Characterization of the 9L gliosarcoma implanted in the Fischer rat: an orthotopic model for a grade IV brain tumor. (24633919)	Bouchet A.... Le Duc G.	2014
45	Gliosarcoma occurrence after surgical clipping of aneurysm - coincidence or causal relationship? (24831372)	Qi S.... Chotai S.	2014
46	A Nonradiated Grade II Glioma That Underwent Delayed Malignant Transformation to a Gliosarcoma with Meningeal Growth and Dissemination. (24971682)	Rech F.... Duffau H.	2014
47	Primary gliosarcoma with long-survival: report of two cases and review of literature. (25337286)	Huo Z.... Liang Z.	2014
48	A Phase III study of radiation therapy (RT) and O(6)-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. (25407559)	Blumenthal D.T.... Rushing E.J.	2014
49	Genetic and pathologic evolution of early secondary gliosarcoma. (23324827)	Codispoti K.E.... Rodriguez F.J.	2014
50	Spinal metastasis of gliosarcoma: Array-based comparative genomic hybridization for confirmation of metastatic spread. (25065849)	Schindler G.... Brenke C.	2014

Genes related to Gliosarcoma

Sources:
⁸Cosmic, ¹³DISEASES, ²¹GeneCards, ⁵⁰Novoseek, ⁵⁴Orphanet
See all MalaCards sources

Genes related to Gliosarcoma (12 elite genes):

(show all 40)

- Elite gene

- Cancer Census gene in COSMIC

id	Symbol	Description	Score	Implication	PubmedIds
1	EGFR	Epidermal Growth Factor Receptor	355.16	Gene fusion ⁵⁴ DISEASES inferred ¹³
2	LZTR1	Leucine Zipper Like Transcription Regulator 1	350.00	Causative somatic mutation ⁵⁴
3	TACC1	Transforming Acidic Coiled-Coil Containing Protein 1	350.00	Gene fusion ⁵⁴
4	FGFR1	Fibroblast Growth Factor Receptor 1	350.00	Gene fusion ⁵⁴
5	SEPT14	Septin 14	350.00	Gene fusion ⁵⁴
6	TACC3	Transforming Acidic Coiled-Coil Containing Protein 3	350.00	Gene fusion ⁵⁴
7	FGFR3	Fibroblast Growth Factor Receptor 3	350.00	Gene fusion ⁵⁴
8	MGMT	O-6-Methylguanine-DNA Methyltransferase	48.44	DISEASES inferred ¹³ GeneCards inferred via : Publications (show sections)
9	TP53	Tumor Protein P53	42.29	DISEASES inferred ¹³
10	GFAP	Glial Fibrillary Acidic Protein	31.49	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Publications (show sections)	2154322, 16729017
11	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic	30.49	DISEASES inferred ¹³
12	CCND3	Cyclin D3	25.62	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Functions (show sections)	10416984
13	PPARG	Peroxisome Proliferator Activated Receptor Gamma	25.00
14	NFKBIA	NFKB Inhibitor Alpha	25.00
15	LHFP	Lipoma HMGIC Fusion Partner	22.29	DISEASES inferred ¹³ GeneCards inferred via : Publications (show sections)
16	FREM2	FRAS1 Related Extracellular Matrix Protein 2	21.71	DISEASES inferred ¹³ GeneCards inferred via : Publications (show sections)
17	NES	Nestin	21.24	DISEASES inferred ¹³ GeneCards inferred via : Publications (show sections)
18	RB1	RB Transcriptional Corepressor 1	20.66	DISEASES inferred ¹³ GeneCards inferred via : Publications (show sections)
19	PTEN	Phosphatase And Tensin Homolog	20.58	DISEASES inferred ¹³ Novoseek inferred ⁵⁰	11355303, 10666371, 9619835
20	SNAI2	Snail Family Transcriptional Repressor 2	20.44	DISEASES inferred ¹³ GeneCards inferred via : Publications (show sections)
21	S100B	S100 Calcium Binding Protein B	17.77	GeneCards inferred via : Publications (show sections)
22	CDK4	Cyclin Dependent Kinase 4	17.39	DISEASES inferred ¹³ Novoseek inferred ⁵⁰	10666371
23	IFNG	Interferon Gamma	17.22	GeneCards inferred via : Publications (show sections)
24	VIM	Vimentin	17.22	GeneCards inferred via : Publications (show sections)
25	IFNB1	Interferon Beta 1	17.22	GeneCards inferred via : Publications (show sections)
26	TWIST1	Twist Family BHLH Transcription Factor 1	17.22	GeneCards inferred via : Publications (show sections)
27	ACTC1	Actin, Alpha, Cardiac Muscle 1	17.22	GeneCards inferred via : Publications (show sections)
28	MMP9	Matrix Metallopeptidase 9	17.22	GeneCards inferred via : Publications (show sections)
29	STOML3	Stomatin Like 3	12.54	DISEASES inferred ¹³ GeneCards inferred via : Publications (show sections)
30	MMP2	Matrix Metallopeptidase 2	7.22	GeneCards inferred via : Publications (show sections)
31	GCH1	GTP Cyclohydrolase 1	7.22	GeneCards inferred via : Publications (show sections)
32	ENO2	Enolase 2	7.22	GeneCards inferred via : Publications (show sections)
33	MSI1	Musashi RNA Binding Protein 1	7.22	GeneCards inferred via : Publications (show sections)
34	GJA1	Gap Junction Protein Alpha 1	6.64	DISEASES inferred ¹³ Novoseek inferred ⁵⁰	9932890, 14529825
35	AP1S2	Adaptor Related Protein Complex 1 Sigma 2 Subunit	5.57	DISEASES inferred ¹³
36	HPD	4-Hydroxyphenylpyruvate Dioxygenase	5.19	DISEASES inferred ¹³
37	EDC3	Enhancer Of MRNA Decapping 3	5.12	DISEASES inferred ¹³
38	CTPS2	CTP Synthase 2	5.11	DISEASES inferred ¹³
39	CPA4	Carboxypeptidase A4	5.01	DISEASES inferred ¹³
40	HSP90AB1	Heat Shock Protein 90 Alpha Family Class B Member 1	5.01	DISEASES inferred ¹³

Variations for Gliosarcoma

Sources:
⁸Cosmic
See all MalaCards sources

Cosmic variations for Gliosarcoma:

⁸

id	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	Conf
1	COSM5033	PTEN	central nervous system,brain,glioma,gliosarcoma	c.389G>A	p.R130Q	5
2	COSM5123	PTEN	central nervous system,brain,glioma,gliosarcoma	c.395G>A	p.G132D	5
3	COSM5154	PTEN	central nervous system,brain,glioma,gliosarcoma	c.697C>T	p.R233*	5
4	COSM10648	TP53	central nervous system,brain,glioma,gliosarcoma	c.524G>A	p.R175H	5
5	COSM476	BRAF	central nervous system,brain,glioma,gliosarcoma	c.1799T>A	p.V600E	5
6	COSM5152	PTEN	central nervous system,brain,glioma,gliosarcoma	c.388C>T	p.R130*	5
7	COSM22413	PDGFRA	central nervous system,brain,glioma,gliosarcoma	c.2472C>T	p.V824V	5
8	COSM5191	PTEN	central nervous system,brain,glioma,gliosarcoma	c.198G>T	p.K66N	5
9	COSM5308	PTEN	central nervous system,brain,glioma,gliosarcoma	c.565A>T	p.R189*	5
10	COSM564	NRAS	central nervous system,brain,glioma,gliosarcoma	c.35G>A	p.G12D	5

Expression for genes affiliated with Gliosarcoma

Sources:
¹⁸Gene Expression Omnibus DataSets
See all MalaCards sources

Search GEO for disease gene expression data for Gliosarcoma.

Pathways for genes affiliated with Gliosarcoma

Sources:
³Cell Signaling Technology, ³⁴KEGG, ⁴²NCBI BioSystems Database, ⁵⁵PathCards, ⁵⁶PharmGKB, ⁵⁸QIAGEN, ⁵⁹R&D Systems, ⁶⁵Thomson Reuters, ⁶⁶Tocris Bioscience
See all MalaCards sources

Pathways related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 29)

id	Super pathways	Score	Top Affiliating Genes
1	Vemurafenib Pathway, Pharmacodynamics⁵⁶	10.2	EGFR, FGFR1, FGFR3
2	Alzheimers Disease Pathway⁵⁸	10.2	EGFR, FGFR1, FGFR3
3	Adherens junction³⁴	10.1	EGFR, FGFR1, SNAI2
4	DNA damage_ATM/ATR regulation of G1/S checkpoint⁶⁵	10.1	CCND3, NFKBIA, TP53
5	RB in Cancer⁴²	10.1	CCND3, RB1, TP53
6	Androgen receptor signaling pathway⁴²	10.0	EGFR, PTEN, RB1
7	Aurora A signaling⁴²	10.0	NFKBIA, TACC1, TACC3, TP53
8	Bladder cancer³⁴	10.0	EGFR, FGFR3, RB1, TP53
9	Neural Stem Cell Differentiation Pathways and Lineage-specific Markers⁵⁹	10.0	FGFR1, FGFR3, GFAP, NES
10	Spinal Cord Injury⁴²	10.0	EGFR, GFAP, RB1, TP53
11	Neural Crest Differentiation⁴²	9.9	FGFR1, FGFR3, GFAP, SNAI2
12	Chronic myeloid leukemia³⁴ Show member pathways Pancreatic cancer³⁴	9.9	EGFR, NFKBIA, RB1, TP53
13	p53 Pathway (RnD)⁵⁹ Show member pathways p53 Pathway⁵⁹	9.9	CCND3, MGMT, PTEN, TP53
14	Integrated Breast Cancer Pathway⁴²	9.9	EGFR, PTEN, RB1, TP53
15	Viral carcinogenesis³⁴	9.9	CCND3, NFKBIA, RB1, TP53
16	HTLV-I infection³⁴	9.9	CCND3, NFKBIA, RB1, TP53
17	Development IGF-1 receptor signaling⁶⁵ Show member pathways IL-4 signaling Pathway⁴² Signal transduction AKT signaling⁶⁵ Immune response IL-4 signaling pathway⁶⁵	9.9	CCND3, NFKBIA, PTEN, TP53
18	Apoptosis Pathway⁶⁶ Show member pathways Akt Pathway⁶⁶ NF-kappaB Pathway⁶⁶	9.9	EGFR, FGFR1, FGFR3, NFKBIA, TP53
19	Small cell lung cancer³⁴	9.9	NFKBIA, PTEN, RB1, TP53
20	Integrated Pancreatic Cancer Pathway⁴²	9.8	EGFR, FGFR1, NFKBIA, PTEN, TP53
21	DNA Damage³	9.8	CCND3, MGMT, RB1, TACC3, TP53
22	Glioblastoma Multiforme⁵⁸	9.8	EGFR, MGMT, PTEN, RB1, TP53
23	Direct p53 effectors⁴²	9.7	EGFR, PTEN, RB1, SNAI2, TP53
24	Central carbon metabolism in cancer³⁴	9.7	EGFR, FGFR1, FGFR3, IDH1, PTEN, TP53
25	PI3K-Akt signaling pathway³⁴	9.7	CCND3, EGFR, FGFR1, FGFR3, PTEN, TP53
26	Glioma³⁴ Show member pathways Endocrine resistance³⁴ Prostate cancer³⁴ Signaling Pathways in Glioblastoma⁴² Breast cancer³⁴ Melanoma³⁴ Non-small cell lung cancer³⁴ EGFR tyrosine kinase inhibitor resistance³⁴ Estrogen signaling pathway³⁴	9.7	EGFR, FGFR1, NFKBIA, PTEN, RB1, TP53
27	MAPK Signaling: Mitogen Stimulation Pathway⁵⁹ Show member pathways Akt Signaling Pathway⁵⁹	9.6	CCND3, EGFR, FGFR1, FGFR3, PTEN, RB1
28	Pathways in cancer³⁴	9.4	EGFR, FGFR1, FGFR3, NFKBIA, PPARG, PTEN
29	ERK Signaling⁵⁸ Show member pathways ILK Signaling⁵⁸ Molecular Mechanisms of Cancer⁵⁸ MAPK Signaling⁵⁸ Rho Family GTPases⁵⁸	9.1	CCND3, EGFR, FGFR1, FGFR3, GFAP, NFKBIA

GO Terms for genes affiliated with Gliosarcoma

Sources:
¹⁹Gene Ontology
See all MalaCards sources

Cellular components related to Gliosarcoma according to GeneCards Suite gene sharing:

id	Name	GO ID	Score	Top Affiliating Genes
1	intermediate filament cytoskeleton	GO:0045111	10.1	GFAP, NES, TACC1

Biological processes related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 12)

id	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of telomerase activity	GO:0051974	10.9	PPARG, TP53
2	positive regulation of phospholipase activity	GO:0010518	10.9	FGFR1, FGFR3
3	negative regulation of macrophage derived foam cell differentiation	GO:0010745	10.8	NFKBIA, PPARG
4	phosphatidylinositol phosphorylation	GO:0046854	10.8	EGFR, FGFR1, FGFR3
5	cellular response to ionizing radiation	GO:0071479	10.8	MGMT, SNAI2, TP53
6	regulation of phosphatidylinositol 3-kinase signaling	GO:0014066	10.7	EGFR, FGFR1, FGFR3
7	phosphatidylinositol-mediated signaling	GO:0048015	10.6	EGFR, FGFR1, FGFR3, PTEN
8	cell proliferation	GO:0008283	10.6	EGFR, PTEN, TACC1, TACC3, TP53
9	salivary gland morphogenesis	GO:0007435	10.6	EGFR, FGFR1
10	negative regulation of apoptotic process	GO:0043066	10.3	EGFR, MGMT, NFKBIA, PTEN, SNAI2, TP53
11	response to organic cyclic compound	GO:0014070	10.2	EGFR, IDH1, MGMT, PPARG, PTEN
12	white fat cell differentiation	GO:0050872	10.2	PPARG, SNAI2

Molecular functions related to Gliosarcoma according to GeneCards Suite gene sharing:

id	Name	GO ID	Score	Top Affiliating Genes
1	fibroblast growth factor-activated receptor activity	GO:0005007	11.0	FGFR1, FGFR3
2	glycoprotein binding	GO:0001948	10.8	EGFR, FGFR1, GFAP
3	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	10.6	EGFR, FGFR1, FGFR3
4	enzyme binding	GO:0019899	10.3	EGFR, NFKBIA, PPARG, PTEN, RB1, TP53
5	protein phosphatase binding	GO:0019903	10.1	EGFR, PPARG, TP53
6	identical protein binding	GO:0042802	10.1	EGFR, FGFR1, NFKBIA, PPARG, PTEN, RB1